嚼口香糖治疗术后恶心呕吐:一项预试验随机对照试验
该预试验将94例腹腔镜或乳腺手术后于PACU发生PONV的女性患者随机分入口服昂丹司琼4 mg静脉注射组或嚼口香糖组,主要结局为PONV完全缓解,非劣效界值为组间差异<15%。符合方案分析中昂丹司琼组5/13(39%)与口香糖组9/12(75%)完全缓解,风险差37%(6.3-67%),P=0.07;两组次要结局无差异,研究流程可行,支持开展更大规模多中心随机对照试验。
要点
- 女性腹腔镜或乳腺手术后PACU发生PONV,嚼口香糖在完全缓解上不劣于昂丹司琼4 mg静脉注射。
- 符合方案分析完全缓解率昂丹司琼组39%、口香糖组75%,风险差37%(6.3-67%),P=0.07。
- 3例口香糖组患者发生PONV时无法咀嚼口香糖,方案可行性良好,支持开展多中心大样本试验。
核心结论
- 在该预试验中,女性腹腔镜或乳腺手术全麻后治疗PONV,嚼口香糖不劣于昂丹司琼4 mg静脉注射。
- 研究结果支持开展更大规模多中心随机对照试验来验证这一新疗法。
研究设计与样本
- 预试验随机对照试验,94例女性患者随机分入口服昂丹司琼4 mg静脉注射组或嚼口香糖组,仅在PACU发生PONV时给予干预。
- 主要结局为PONV完全缓解,非劣效定义为符合方案分析中组间差异<15%。
- 次要结局包括PACU停留时间、止吐补救用药使用及止吐治疗可接受性,并评估在更大试验中实施方案的可行性。
主要发现
- PACU内PONV发生于昂丹司琼组13例(28%)和口香糖组15例(31%),P=0.75。
- 符合方案分析中PONV完全缓解为昂丹司琼组5/13(39%)对口服香糖组9/12(75%),风险差37%(6.3-67%),P=0.07。
- 3例口香糖组患者发生PONV时无法咀嚼口香糖。
- 两组次要结局无差异。
- 招募情况满意,麻醉医生和护士接受方案,数据收集完整。
关键数值与推荐
- 非劣效界值定义为符合方案分析中组间差异<15%。
- 昂丹司琼剂量为4 mg静脉注射。
- PONV完全缓解率:昂丹司琼组39%(5/13),口香糖组75%(9/12),风险差37%(6.3-67%),P=0.07。
临床怎么用
- 对于女性腹腔镜或乳腺手术后PACU发生PONV的患者,嚼口香糖可作为昂丹司琼4 mg静脉注射之外的一种治疗选择。
- 需注意部分患者发生PONV时无法咀嚼口香糖,实施时应评估患者咀嚼能力。
局限性
- 本研究为预试验,样本量小(94例),主要目的是评估可行性而非确证疗效。
- 符合方案分析中完全缓解的组间比较P=0.07,未达到传统统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A novel treatment, chewing gum, may be non-inferior to ondansetron in inhibiting postoperative nausea and vomiting (PONV) in female patients after laparoscopic or breast surgery. In this pilot study, we tested the feasibility of a large randomized controlled trial. METHODS: We randomized 94 female patients undergoing laparoscopic or breast surgery to ondansetron 4 mg i.v. or chewing gum if PONV was experienced in the postanaesthesia care unit (PACU). The primary outcome was full resolution of PONV, with non-inferiority defined as a difference between groups of <15% in a per protocol analysis. Secondary outcomes were PACU stay duration, anti-emetic rescue use, and acceptability of anti-emetic treatment. The feasibility of implementing the protocol in a larger trial was assessed. RESULTS: Postoperative nausea and vomiting in the PACU occurred in 13 (28%) ondansetron patients and 15 (31%) chewing gum patients (P=0.75). Three chewing gum patients could not chew gum when they developed PONV. On a per protocol basis, full resolution of PONV occurred in five of 13 (39%) ondansetron vs nine of 12 (75%) chewing gum patients [risk difference 37% (6.3-67%), P=0.07]. There was no difference in secondary outcomes between groups. Recruitment was satisfactory, the protocol was acceptable to anaesthetists and nurses, and data collection was complete. CONCLUSIONS: In this pilot trial, chewing gum was not inferior to ondansetron for treatment of PONV after general anaesthesia for laparoscopic or breast surgery in female patients. Our findings demonstrate the feasibility of a larger, multicentred randomized controlled trial to investigate this novel therapy. CLINICAL TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry: ACTRN12615001327572.
引用
- Darvall JN, Handscombe M, Leslie K, et al. Chewing gum for the treatment of postoperative nausea and vomiting: a pilot randomized controlled trial. Br J Anaesth. 2017. PMID: 28039245. doi:10.1093/bja/aew375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。